ECSP22067279A - Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo - Google Patents

Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo

Info

Publication number
ECSP22067279A
ECSP22067279A ECSENADI202267279A ECDI202267279A ECSP22067279A EC SP22067279 A ECSP22067279 A EC SP22067279A EC SENADI202267279 A ECSENADI202267279 A EC SENADI202267279A EC DI202267279 A ECDI202267279 A EC DI202267279A EC SP22067279 A ECSP22067279 A EC SP22067279A
Authority
EC
Ecuador
Prior art keywords
purification
chemical formula
synthesis
sglt inhibitor
compound
Prior art date
Application number
ECSENADI202267279A
Other languages
English (en)
Inventor
Youn Jung Yoon
Hee Kyoon Yoon
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of ECSP22067279A publication Critical patent/ECSP22067279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención proporciona un producto intermedio útil para la síntesis de un inhibidor de SGLT y un método para preparar un inhibidor de SGLT usando el mismo. Según la presente invención, al desarrollar un compuesto de fórmula química 5 correspondiente a un producto intermedio novedoso, puede resolverse la dificultad de purificación con los procedimientos existentes, pueden satisfacerse los requisitos de calidad para sustancias relacionadas con una única etapa de purificación y puede resolverse el problema de control de calidad en cada etapa realizando varias etapas in situ. El método para sintetizar un compuesto de fórmula química 1 mediante el uso de un compuesto de fórmula química 5, según la presente invención, permite la purificación en la etapa de síntesis de un compuesto de fórmula química 5, resolviendo de ese modo los problemas de los procedimientos de síntesis existentes, en los que los requisitos de calidad para sustancias relacionadas eran difíciles de controlar etapa por etapa debido a un procedimiento continuo, y minimizando la cantidad de sustancias relacionadas en el producto final. Además, a medida que aumenta el número de etapas de purificación, el procedimiento puede simplificarse porque la purificación no se realiza necesariamente dos o más veces en una etapa como en la técnica anterior, maximizando de ese modo el rendimiento de producción de un derivado de difenilmetano según la fórmula química 1.
ECSENADI202267279A 2020-02-27 2022-08-26 Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo ECSP22067279A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200024525 2020-02-27

Publications (1)

Publication Number Publication Date
ECSP22067279A true ECSP22067279A (es) 2022-09-30

Family

ID=77490302

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202267279A ECSP22067279A (es) 2020-02-27 2022-08-26 Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo

Country Status (13)

Country Link
US (1) US20230096670A1 (es)
EP (1) EP4112612A4 (es)
JP (1) JP7442663B2 (es)
KR (1) KR102572714B1 (es)
CN (1) CN115087649A (es)
BR (1) BR112022014762A2 (es)
CA (1) CA3169604A1 (es)
CL (1) CL2022002326A1 (es)
CO (1) CO2022011686A2 (es)
EC (1) ECSP22067279A (es)
MX (1) MX2022010220A (es)
PE (1) PE20221498A1 (es)
WO (1) WO2021172955A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530124A (en) * 1994-06-30 1996-06-25 The Dupont Merck Pharmaceutical Company Method for preparing cyclic ureas and their use for the synthesis of HIV protease inhibitors
ME02702B (me) * 2008-08-22 2017-10-20 Theracos Sub Llc Postupci za pripremu inhibitora sgl t2
WO2012033390A2 (en) * 2010-09-10 2012-03-15 Green Cross Corporation Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
WO2012165914A2 (en) * 2011-06-01 2012-12-06 Green Cross Corporation Novel diphenylmethane derivatives as sglt2 inhibitors
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
US10174010B2 (en) * 2014-03-19 2019-01-08 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
WO2016098016A1 (en) * 2014-12-17 2016-06-23 Dr. Reddy’S Laboratories Limited Process for the preparation of sglt2 inhibitors
ES2898336T3 (es) 2016-06-17 2022-03-07 Dae Woong Pharma Derivado de difenilmetano en forma cristalina
CN108530408A (zh) * 2018-04-13 2018-09-14 海门慧聚药业有限公司 制备达格列净的方法
BR112021002523A2 (pt) * 2018-08-13 2021-05-04 Daewoong Pharmaceutical Co., Ltd. método para preparar um composto

Also Published As

Publication number Publication date
CO2022011686A2 (es) 2022-08-30
PE20221498A1 (es) 2022-09-29
CL2022002326A1 (es) 2023-02-10
KR102572714B1 (ko) 2023-08-31
MX2022010220A (es) 2022-10-10
BR112022014762A2 (pt) 2022-10-11
CN115087649A (zh) 2022-09-20
KR20210109476A (ko) 2021-09-06
CA3169604A1 (en) 2021-09-02
JP2023514754A (ja) 2023-04-07
JP7442663B2 (ja) 2024-03-04
EP4112612A1 (en) 2023-01-04
EP4112612A4 (en) 2024-04-03
WO2021172955A1 (ko) 2021-09-02
US20230096670A1 (en) 2023-03-30
AU2021225706A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
NZ594077A (en) Process for production of delta-9-tetrahydrocannabinol
AR061112A1 (es) Procedimientos para la produccion de derivados de benzopiran-2-ol, fesoterodina y un derivado de la tolterodina e intermediarios de sintesis de los citados procesos.
BR112018076243A2 (pt) método para produção de derivado de difenil metano
DE502004011239D1 (de) Verfahren zur dehydratisierung substituierter 4-dimethylamino-2-aryl-butan-2-ol-verbindungen und verfahren zur herstellung substituierter dimethyl-(3-katalyse
BR112019005294A2 (pt) processo para preparar (±)-2-exo-(2-metilbenzilóxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano de fórmula (i) e método para prevenir ou reduzir a formação de depósitos no interior de um reator
DE60316573D1 (de) Verfahren und vorrichtung für die herstellung einer ein bituminöses bindemittel enthaltenden baumischung
EA202191502A1 (ru) Способ получения апиксабана
CO2021009253A2 (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de síntesis
ECSP22067279A (es) Intermedio útil para la síntesis de un inhibidor de sglt y método para preparar un inhibidor de sglt utilizando el mismo
MX2020013827A (es) Proceso de preparacion de compuestos triciclicos.
PH12021550297A1 (en) Preparation of intermediate useful for synthesis of sglt inhibitor
ATE480530T1 (de) Herstellungsverfahren für optisch aktive verbindungen
ATE493426T1 (de) Herstellungsverfahren für tagatose unter anwendung einer galactoseisomerisierung mit hoher ausbeute
ATE259366T1 (de) Herstellungsverfahren für ein bekanntes terazolderivat
MX2018010128A (es) Toxina nueva y metodo de preparacion de un intermediario de la misma.
MX2021005343A (es) Proceso para la preparacion de isoxazolinas opticamente enriquecidas.
Behr et al. Synthesis of 6-deoxy-homoDMDP and its C (5)-epimer: Absolute stereochemistry of natural products from Hyacinthus orientalis
BRPI0514000A (pt) método para a produção de derivados de diarilcicloalquila
MX2019004141A (es) Proceso para la obtencion de los enantiomeros del praziquantel y sus derivados 4'-hidroxilados.
DE502008002407D1 (de) Verfahren zur herstellung carbonat-terminierter verbindungen
BR112021020443A2 (pt) Enol-acetatos(ii)
FR848739A (fr) Procédé de fabrication de persels, tels que les persulfates, par électrolyse
BRPI0603912A (pt) processo para produção de acetais, acetais e seus usos
DE502005003019D1 (de) Verfahren zur herstellung der enantiomeren formen von 2,3-diaminopropionsäurederivaten
BR112022020380A2 (pt) Um processo e aparelho para preparar uma composição de estireno purificada a partir de matéria-prima que contém estireno